Also recommended for those with a personal or family history of:
For recurrent or Stage IV breast cancer:
For upfront settings in ovarian cancer:
For recurrence settings in ovarian cancer:
Uterine Neoplasms:
Recommended for individuals with a personal history of:
For metastatic colorectal cancer (mCRC):
Biomarker testing is recommended for all eligible NSCLC patients to evaluate suitability for targeted therapies or immunotherapies, which have shown improved survival outcomes compared to chemotherapy, particularly for patients with Stage IV (M1a, M1b, M1c) and resectable early-stage NSCLC.
Molecular profiling may be considered in rare cases of relapsed or extensive-stage SCLC, especially for non-smokers or those with a distant smoking history, to guide therapy if not previously done.
To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.